...
首页> 外文期刊>Journal of biomedical science. >Complexation to Cationic Microspheres of Double-Stranded Peptide Nucleic Acid-DNA Chimeras Exhibiting Decoy Activity.
【24h】

Complexation to Cationic Microspheres of Double-Stranded Peptide Nucleic Acid-DNA Chimeras Exhibiting Decoy Activity.

机译:具有诱饵活性的双链肽核酸-DNA嵌合体与阳离子微球的络合。

获取原文
获取原文并翻译 | 示例
           

摘要

The major aim of this paper was to determine whether cationic microspheres (CM), consisting of the permeable polymer Eudragit((R)) RS 100 plus the cationic surfactant dioctadecyl-dimethyl-ammonium bromide (DDAB(18)), could bind to double-stranded peptide nucleic acid PNA-DNA-PNA (PDP) chimeras exhibiting decoy activity against NF-kappaB transcription factors. Microspheres were produced by the 'solvent evaporation method' and centrifugation at 500, 1,000 and 3,000 rpm to obtain different-sized microparticles. Microsphere morphology, size and size distribution were determined by optical and electron microscopy observations. In order to determine their binding activity, double-stranded DNA-based and PDP-based decoy molecules were incubated with different amounts of microparticles in the presence of 100 ng of either (32)P-labeled DNA-DNA or DNA-PDP hybrid molecules or cold PDP-PDP hybrids. The complexes were analyzed by agarose gel electrophoresis. The resistance of (32)P-labeled DNA-DNA and DNA-PDP molecules in the presence of serum or cellular extracts was evaluated after binding to CM by gel electrophoresis analysis. DDAB(18) Eudragit RS 100 microspheres are able to bind to DNA-PDP and PDP-PDP hybrids, to deliver these molecules to target cells and to protect DNA-PDP molecules from enzymatic degradation in simulated biological fluids. In addition, when assayed in ex vivo conditions, DDAB(18) Eudragit RS 100 microspheres exhibited low toxicity. The results presented in this paper demonstrate that CM can be considered suitable formulations for pharmacogenomic therapy employing double-stranded PDP chimeras. Copyright 2004 National Science Council, ROC and S. Karger AG, Basel
机译:本文的主要目的是确定由渗透性聚合物Eudragit(R)RS 100加上阳离子表面活性剂二十八烷基二甲基溴化铵(DDAB(18))组成的阳离子微球(CM)是否能与双键结合链肽核酸PNA-DNA-PNA(PDP)嵌合体表现出对NF-κB转录因子的诱饵活性。通过“溶剂蒸发法”制备微球,并以500、1,000和3,000 rpm离心获得不同大小的微粒。通过光学和电子显微镜观察确定微球的形态,大小和大小分布。为了确定它们的结合活性,在100 ng(32)P标记的DNA-DNA或DNA-PDP杂合分子的存在下,将基于双链DNA和基于PDP的诱饵分子与不同数量的微粒一起孵育或冷PDP-PDP混合体。通过琼脂糖凝胶电泳分析复合物。通过凝胶电泳分析与CM结合后,评估在血清或细胞提取物存在下(32)P标记的DNA-DNA和DNA-PDP分子的抗性。 DDAB(18)Eudragit RS 100微球能够与DNA-PDP和PDP-PDP杂化物结合,将这些分子递送至靶细胞并保护DNA-PDP分子在模拟生物流体中不被酶降解。此外,当在离体条件下测定时,DDAB(18)Eudragit RS 100微球显示出低毒性。本文提出的结果表明,CM可被认为是采用双链PDP嵌合体进行药物基因组治疗的合适制剂。 2004年,美国国家科学委员会(ROC)和S. Karger AG(巴塞尔)版权所有

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号